Overview
McDermott Will & Emery has advised Cilcare, a leading biotech company specializing in auditory sciences, on an exclusive Option Agreement with Shionogi, a pharmaceutical company, for innovative hearing disorder treatment.
This exclusive option agreement grants Shionogi the right to license global rights to CIL001 and/or CIL003, two promising drug candidates aimed at treating hearing disorders, with a particular focus on addressing the increasing prevalence of hidden hearing loss and tinnitus.
The McDermott team that advised Cilcare comprised:
- Emmanuelle Trombe, partner, Natacha Vasak and Oriana Castelli, associates, on corporate aspects
- Côme de Saint-Vincent, Counsel, on tax aspects
- Charles de Raignac, associate, on intellectual property aspects
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
